Shield Thera Share News (STX)

Shield Thera Information

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes

Get Live Data

5.75 -0.10 (-1.71%)

Bid:

5.70

Ask:

5.80

Spread: 0.10 (1.754%)

Market Cap: £61.50m

Last checked at -

Intraday Shield Thera Share Chart

REMOVE ADS

Shield Therapeutics shares rise as US sales boost interim revenue

Thu, 21st Aug 2025 12:58

(Alliance News) - Shield Therapeutics PLC on Thursday reported a narrowing of its half-year loss, bolstered by US sales and milestone payments globally, as it backed its full-year cash flow guidance.

The Newcastle, England-based commercial-stage pharmaceutical company said its pretax loss narrowed USD9.4 million in the six months that ended June 30, from USD15.5 million a year earlier.

Shares in Shield Therapeutics were 6.9% higher at 7.16 pence on Thursday afternoon in London.

Helping its loss narrow was a 77% advance in revenue to USD21.4 million from USD12.1 million, with Shield Therapeutics benefitting from increased US sales of Accrufer. Sales in the region climbed 75% to USD19.2 million from USD11.0 million.

Accrufer is the company's oral treatment for patients with iron deficiency with or without anaemia.

Outside of the US, the company reported USD2.2 million in milestones and royalties revenue from partners in Europe, Canada and Japan, doubling from the year before.

A reduction in operating costs further supported the bottom line, down 17% to USD15.6 million from USD18.8 million.

Cash and cash equivalents improved to USD10.8 million at June 30, up from USD6.5 million at December 31.

Looking ahead, the company backed its cash flow guidance for the full-year, with it expecting to turn cash flow positive by the end of the year.

"We are encouraged by Accrufer's strong performance in H1 2025, following the increasing market adoption of Accrufer, which further validates its substantial potential. Operationally, we made significant progress globally, including the launch of Accrufer in Canada, a new licensing agreement in Japan, and the successful completion of a key Phase 3 study in China. We also submitted regulatory filings for paediatric use in both Europe and the US following positive trial results," said Chief Executive Anders Lundstrom

"These results reflect the growing demand for Accrufer and the successful execution of our strategy to expand access to patients worldwide," continued Lundstrom.

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com